Q3 Earnings Forecast for Medtronic Issued By William Blair

Medtronic PLC (NYSE:MDT) – Equities research analysts at William Blair upped their Q3 2026 EPS estimates for Medtronic in a research report issued on Wednesday, November 19th. William Blair analyst B. Vazquez now expects that the medical technology company will post earnings per share of $1.36 for the quarter, up from their previous forecast of $1.34. The consensus estimate for Medtronic’s current full-year earnings is $5.46 per share.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The company had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same period in the prior year, the business posted $1.26 earnings per share. The firm’s revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS.

Several other analysts have also weighed in on the company. The Goldman Sachs Group set a $111.00 target price on Medtronic and gave the company a “neutral” rating in a report on Wednesday. Stifel Nicolaus increased their price objective on shares of Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Robert W. Baird lifted their target price on shares of Medtronic from $103.00 to $109.00 and gave the stock a “neutral” rating in a research report on Wednesday. Daiwa Capital Markets increased their price target on shares of Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Finally, Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research note on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $109.72.

Medtronic Stock Performance

MDT opened at $101.16 on Friday. Medtronic has a 1-year low of $79.29 and a 1-year high of $102.59. The stock has a market cap of $129.76 billion, a P/E ratio of 27.87, a P/E/G ratio of 2.42 and a beta of 0.77. The stock’s 50 day simple moving average is $95.04 and its 200 day simple moving average is $90.88. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50.

Institutional Investors Weigh In On Medtronic

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Brighton Jones LLC boosted its position in shares of Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after acquiring an additional 37,265 shares during the last quarter. PFG Advisors raised its stake in Medtronic by 55.0% during the first quarter. PFG Advisors now owns 4,144 shares of the medical technology company’s stock worth $372,000 after purchasing an additional 1,471 shares during the period. Venturi Wealth Management LLC boosted its holdings in shares of Medtronic by 9.5% in the 1st quarter. Venturi Wealth Management LLC now owns 6,982 shares of the medical technology company’s stock valued at $627,000 after purchasing an additional 608 shares during the last quarter. J. W. Coons Advisors LLC purchased a new stake in shares of Medtronic during the 1st quarter valued at $216,000. Finally, AE Wealth Management LLC increased its holdings in shares of Medtronic by 7.2% during the 1st quarter. AE Wealth Management LLC now owns 8,899 shares of the medical technology company’s stock worth $800,000 after buying an additional 597 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the sale, the executive vice president directly owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. The trade was a 19.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William R. Jellison purchased 2,500 shares of the business’s stock in a transaction on Monday, August 25th. The stock was acquired at an average price of $92.37 per share, with a total value of $230,925.00. Following the completion of the acquisition, the director directly owned 5,000 shares in the company, valued at $461,850. The trade was a 100.00% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.